@entity4181 plus XXXX : an effective treatment for metastatic colon cancer.

@entity1 @entity4181 @entity137 @entity390 @entity5 @entity294 @entity425 @entity787 @entity1398 @entity3 @entity14 @entity1487
In Columbus, OH, 46 @entity1 with measurable metastatic @entity14 were treated with @entity4181 (LV) 80 mg/m2/20 h intravenous (IV) infusion followed by @entity1487 ( @entity1487 ) 400 mg/m2 IV bolus daily for three days and then once weekly. Many @entity1 had liver (62%) and/or multisite @entity3 (53%), @entity787 ( @entity787 ) greater than 10 (76%), documented @entity5 progression before entry (51%), and @entity5 -related symptoms (36%), but also good performance status (84%). Prior therapy consisted of radiotherapy (RT) in 18%, chemotherapy in 22%, both in 4%, and none in 56%. There were 36% objective responses and 31% stabilization, which we believe is a significant change in the natural history of these @entity1 . Median survival was 8 months. Improved survival was seen in @entity1 with single- rather than multiple-site involvement. Decreasing @entity787 levels were seen in 59% (always in responders or @entity1 with stable disease), and correlated with longer survival time (11.0 v 5.5 months, P = 0.01). Palliation of @entity5 related symptoms occurred in 75%, with or without antitumor effect. One @entity1 with prior RT died of @entity1398 after only the three-day load, so we now recommend only weekly therapy in previously radiated @entity1 . Otherwise, @entity137 was mild, manifest as @entity425 in 62%, @entity390 in 53%, or @entity294 in 47%, which was the most common dose-limiting side effect. The occurrence or absence of @entity137 did not predict outcome. Because of equivalent efficacy, mild @entity137 , and less expense, this regimen should be considered for @entity1 who desire therapy.
